Averroes Pharmaceuticalssdn BHD MLY

Averroes Pharmaceuticals Sdn. Bhd. is a Malaysian pharmaceutical company established in April 2001, specializing in the supply of high-quality generic medications across various therapeutic categories. The company is headquartered at 3-8-1 & 3-9-1 Block 3, Presint Alami, Worldwide Business Centre 2, Persiaran Akuatik, Section 13, 40000 Shah Alam, Selangor, Malaysia. (averroespharma.com.my) Averroes Pharmaceuticals operates as a pharmaceutical importer and distributor, focusing on both government and private sector markets within Malaysia. Since 2010, the company has expanded its international business, aiming to become a market leader in the industry by introducing new products and services. (ricebowl.my)

Averroes Pharmaceuticals maintains a comprehensive distribution network within Malaysia, supported by a warehouse facility exceeding 5,000 square feet. This infrastructure enables the company to efficiently manage inventory and fulfill orders across the country. The company's strategic location in Shah Alam, Selangor, positions it advantageously to serve both domestic and international markets, including Brunei and Singapore. (averroespharma.com.my)

In Malaysia's pharmaceutical supply chain, Averroes Pharmaceuticals functions primarily as a pharmaceutical importer and distributor. The company imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from various international suppliers, notably from India. By focusing on the importation and distribution of these finished products, Averroes Pharmaceuticals plays a crucial role in ensuring the availability of quality generic medications in the Malaysian market.

Averroes Pharmaceuticals demonstrates a high degree of supplier concentration, with 97% of its imports sourced from Karnataka Antibiotics and Pharmaceuticals Limited (KAPL) in India. This significant reliance on a single supplier indicates a strategic choice to maintain consistent product quality and supply chain efficiency. However, such concentration also exposes the company to potential risks associated with supplier dependency, including supply disruptions or changes in supplier terms. The stability of this relationship is evidenced by the substantial volume of shipments and the dominance of KAPL in Averroes Pharmaceuticals' import portfolio.

Averroes Pharmaceuticals' supply chain resilience is closely tied to its reliance on KAPL for the majority of its imported products. While this partnership ensures consistent product quality, the lack of diversified suppliers may pose challenges in the event of supply chain disruptions. The company's import data indicates a limited number of suppliers, suggesting a need for strategic diversification to enhance supply chain robustness. Additionally, the company's focus on importing finished pharmaceutical formulations from India suggests a streamlined supply chain with established logistics routes.

The sourcing pattern of Averroes Pharmaceuticals, characterized by a heavy reliance on KAPL, positions the company to benefit from consistent product quality and favorable terms. However, this concentration also presents strategic risks, including potential supply chain vulnerabilities and limited negotiation leverage. For Indian exporters, this presents an opportunity to become alternative suppliers to Averroes Pharmaceuticals, provided they can meet the company's quality standards and supply requirements. Diversifying the supplier base could lead to enhanced supply chain resilience and reduced dependency on a single source.

In Malaysia, the National Pharmaceutical Regulatory Agency (NPRA), under the Ministry of Health, is responsible for regulating pharmaceutical products. The importation and sale of pharmaceutical products are governed by the Control of Drugs and Cosmetics Regulations 1984, which require that all pharmaceutical products be registered with the Drug Control Authority before they can be imported and sold. This regulatory framework ensures that imported pharmaceutical products meet the necessary safety, efficacy, and quality standards.

To import pharmaceutical products into Malaysia, companies must obtain an Import Licence issued by the Director of Pharmaceutical Services under Regulation 12(1)(d) of the Control of Drugs and Cosmetics Regulations 1984. Additionally, Good Manufacturing Practice (GMP) certification is mandatory for manufacturers to ensure product quality. Malaysia recognizes GMP certifications from reputable international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications to comply with Malaysian regulations. (npra.gov.my)

Imported pharmaceutical products must undergo batch testing to verify their quality and compliance with Malaysian standards. Stability studies are required to ensure that products maintain their efficacy and safety throughout their shelf life. Labeling requirements include the use of the Malay language for all product information, ensuring that consumers can understand the usage and safety instructions. Serialization mandates may also apply to facilitate traceability and prevent counterfeit products from entering the market.

Between 2024 and 2026, Malaysia has implemented several policy changes affecting the importation of pharmaceutical products. These include stricter enforcement of GMP certification requirements, updates to the registration process for imported drugs, and enhanced monitoring of pharmaceutical imports to prevent the entry of unregistered or counterfeit products. Importers must stay informed about these regulatory changes to ensure compliance and maintain uninterrupted supply chains.

Averroes Pharmaceuticals focuses on importing antibiotics, particularly ampicillin and benzylpenicillin, which constitute the majority of its import portfolio. This strategic emphasis aligns with the high demand for antibiotics in Malaysia, driven by the need to address various bacterial infections. The company's commitment to expanding its product portfolio to include new chemical entities (NCEs) and biologic products since 2016 indicates a proactive approach to meeting evolving market demands and enhancing treatment options for patients. (averroespharma.com.my)

Averroes Pharmaceuticals primarily sources generic drugs from India, focusing on finished pharmaceutical formulations. This sourcing strategy allows the company to offer cost-effective alternatives to branded medications while maintaining quality standards. The company's import data reveals a preference for antibiotics, reflecting the therapeutic areas with the highest demand in the Malaysian market.

Based on its product mix, Averroes Pharmaceuticals serves multiple segments of the Malaysian pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's focus on both government and private sector markets positions it as a versatile supplier capable of meeting diverse healthcare needs across the country.

There is a realistic opportunity for new Indian suppliers to enter the Malaysian market by partnering with Averroes Pharmaceuticals. The company's current sourcing pattern indicates a need for supplier diversification to enhance supply chain resilience. Indian exporters can leverage this opportunity by ensuring compliance with Malaysian regulatory requirements, obtaining necessary certifications, and meeting the quality standards expected by Averroes Pharmaceuticals.

Indian exporters seeking to supply Averroes Pharmaceuticals and the Malaysian market must obtain GMP certifications recognized by Malaysian authorities, such as WHO GMP or PIC/S. Additionally, they must ensure that their products are registered with the Drug Control Authority in Malaysia and comply with all labeling and packaging requirements, including the use of the Malay language. Adherence to these standards is essential for successful market entry.

Indian exporters should initiate contact with Averroes Pharmaceuticals by presenting their product portfolios and demonstrating compliance with Malaysian regulatory standards. Participating in tenders and responding to requests for proposals can enhance visibility and credibility. Developing a clear regulatory filing strategy, including obtaining necessary certifications and registrations, is crucial. Establishing a timeline for product registration and market entry, in collaboration with Averroes Pharmaceuticals, will facilitate a smooth integration into the Malaysian market.